Tag: stelara forecast

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Stelara (Ustekinumab) Market Size, Value And Growth Trajectory Through 2030

The stelara (ustekinumab) market size has observed robust growth in recent years. It is projected to expand from $11.85 million in 2025 to $12.54 million in 2026, reflecting a compound annual growth rate (CAGR) of 5.9%. The historical expansion can be attributed to factors such as limitations of conventional immunosuppressants, a rising prevalence of autoimmune diseases, strong clinical efficacy data, hospital-based biologic administration, and the demand for durable remission.

The stelara (ustekinumab) market size is anticipated to demonstrate robust expansion in the coming years, with projections indicating it will reach $15.57 million in 2030, growing at a compound annual growth rate (CAGR) of 5.5%. This growth throughout the forecast period is attributable to an increase in inflammatory bowel disease cases, an expansion of biologic reimbursement coverage, patients preferring less frequent dosing, the impact of biosimilar competition, and enhancements in biologic delivery devices. Significant trends for the forecast period include the rising utilization of targeted biologic therapies, an expansion of indications for autoimmune diseases, a transition towards long-term maintenance treatment strategies, increasing adoption of subcutaneous biologics, and a rise in home-based administration.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=56508766&type=smp&name=Stelara%20%28Ustekinumab%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Stelara (Ustekinumab) Market Industry Drivers: What’s Behind The Revenue Growth?

The expanding population of individuals with psoriasis is projected to drive the expansion of the stelara (ustekinumab) market in the future. Psoriasis is characterized by a chronic autoimmune condition where accelerated skin cell turnover leads to distinct red, scaly patches. This increase in psoriasis prevalence stems from various factors such as enhanced diagnostic capabilities, environmental influences, genetic susceptibility, and an aging demographic. stelara (ustekinumab) operates by targeting and blocking interleukin-12 and interleukin-23, which effectively alleviates inflammation and plaque formation in psoriasis patients. This action facilitates improved skin clearance and sustained symptom management, thereby significantly enhancing their quality of life. As an illustration, a report from August 2024 by the National Psoriasis Foundation (NPF), a US-based non-profit, indicates that psoriasis affects approximately 3% of U.S. adults aged 20 and older, accounting for over 7. million people. Furthermore, an estimated 600,000 adults in the country are thought to have psoriasis without a formal diagnosis. Consequently, the growing incidence of psoriasis patients is anticipated to boost the growth of the stelara (ustekinumab) market.

Stelara (Ustekinumab) Market Segment Landscape And Growth Outlook

The stelara (ustekinumab) market covered in this report is segmented –

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications

2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Pediatric, Adult, Geriatric

#Stelara (Ustekinumab) Market Growth Trends: What’s Shaping The Future Outlook?

Leading companies in the stelara (ustekinumab) market are developing innovative products, such as biosimilars to stelara, to offer a cost-effective treatment choice for patients with chronic inflammatory conditions. Stelara biosimilars are biologically analogous medicines designed to emulate the therapeutic effects of Stelara (Ustekinumab), targeting IL-12 and IL-23 for the treatment of autoimmune conditions like psoriasis and psoriatic arthritis. For instance, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is distinguished by its wide indications, providing treatment for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. It is also uniquely approved for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it adaptable across different age groups. This extensive coverage positions IMULDOSA as a valuable alternative for managing various immune-mediated inflammatory diseases.

Stelara (Ustekinumab) Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson

View The Full Stelara (Ustekinumab) Market Report:

https://thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Stelara (Ustekinumab) Market Geographic Analysis: Where Is Demand Accelerating Fastest?

North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Stelara (Ustekinumab) Market Size Forecast: How Large Could The Market Become By 2030?

The stelara (ustekinumab) market has experienced robust expansion over recent years. Projected figures indicate an increase from $11.85 million in 2025 to $12.54 million in 2026, achieving a compound annual growth rate of 5.9%. This historic growth has been driven by factors such as the constraints of traditional immunosuppressants, the growing incidence of autoimmune conditions, compelling evidence of clinical effectiveness, biologic administration within hospital settings, and a strong desire for sustained remission.

Over the coming years, the market for Stelara (ustekinumab) is anticipated to undergo substantial expansion. By 2030, a valuation of $15.57 million is projected, driven by a compound annual growth rate (CAGR) of 5.5%. Several factors are expected to fuel this forecasted growth, including a rise in inflammatory bowel disease cases, widening reimbursement for biologic therapies, a growing patient inclination toward reduced dosing frequency, the impact of biosimilar competition, and advancements in biologic delivery systems. Key trends shaping the forecast period encompass an increasing reliance on targeted biologic treatments, the broadening of autoimmune disease indications, a transition toward long-term maintenance strategies, greater acceptance of subcutaneous biologic formulations, and a rise in at-home administration practices.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Stelara (Ustekinumab) Market Opportunity Drivers: What Is Creating New Revenue Potential?

The growing number of individuals diagnosed with psoriasis is anticipated to drive expansion in the Stelara (ustekinumab) market moving forward. Psoriasis patients are those affected by a chronic autoimmune condition that speeds up skin cell production, leading to red, scaly lesions. This increase in psoriasis cases is linked to various causes, such as enhanced diagnostic methods, environmental factors, hereditary influences, and an older demographic. Stelara (ustekinumab) works by targeting and blocking interleukin-12 and interleukin-23, which assists psoriasis patients by significantly lowering inflammation and plaque buildup, resulting in better skin clearing and sustained symptom control, thereby improving their overall well-being. As an example, in August 2024, a report from the National Psoriasis Foundation (NPF), a U.S.-based nonprofit, indicated that psoriasis affects roughly 3% of American adults aged 20 and older, equating to over 7 million people. Furthermore, it is estimated that about 600,000 adults in the country have psoriasis but have not yet received a diagnosis. Consequently, the rising prevalence of psoriasis patients is projected to boost the Stelara (ustekinumab) market.

Stelara (Ustekinumab) Market Segment Performance And Strategic Opportunities

The stelara (ustekinumab) market covered in this report is segmented –

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications

2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Pediatric, Adult, Geriatric

Stelara (Ustekinumab) Market Innovation Trends Driving Future Development

Key players in the stelara (ustekinumab) market are introducing groundbreaking products, specifically biosimilars of this drug, aimed at delivering affordable therapeutic alternatives for individuals suffering from chronic inflammatory disorders. These biosimilars are biologically alike medications engineered to mirror the clinical benefits of Stelara (Ustekinumab) by acting on IL-12 and IL-23 to address autoimmune conditions such as psoriasis and psoriatic arthritis. A notable example occurred in October 2024, when Accord BioPharma Inc., a biopharmaceutical firm headquartered in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for IMULDOSA (ustekinumab-srlf), a biosimilar reference to Johnson & Johnson’s STELARA (ustekinumab). What sets IMULDOSA apart is its extensive list of approved uses, encompassing treatment for adults dealing with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. Additionally, it is uniquely indicated for pediatric patients aged six years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, offering flexibility across different age demographics. Such broad applicability establishes IMULDOSA as a significant therapeutic choice for managing a spectrum of immune-mediated inflammatory conditions.

Stelara (Ustekinumab) Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson

Access The Complete Stelara (Ustekinumab) Market Report:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Stelara (Ustekinumab) Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Estimated Growth In Market Size Of The Stelara (Ustekinumab) Market During 2026–2030?

The market size for stelara (ustekinumab) has shown strong expansion in recent years. It is anticipated to increase from $11.85 million in 2025 to $12.54 million in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The growth observed in the past can be attributed to factors such as the drawbacks of traditional immunosuppressants, the increasing occurrence of autoimmune diseases, robust clinical efficacy information, the common practice of hospital-based biologic administration, and the ongoing need for lasting remission.

The market size for stelara (ustekinumab) is projected to experience robust expansion over the coming years. It will grow to $15.57 million in 2030 at a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the forecast timeframe is attributable to several factors, including an increase in inflammatory bowel disease instances, broadened biologic reimbursement access, patients favoring less frequent dosing schedules, the influence of biosimilar competition, and advancements in biologic delivery devices. Key trends identified for the forecast period encompass an increasing reliance on targeted biologic therapies, a wider range of indications for autoimmune diseases, a move towards long-term maintenance therapies, the increasing use of subcutaneous biologics, and a rise in at-home administration.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

Which Significant Factors Are Encouraging Growth In The Stelara (Ustekinumab) Market?

An increasing number of individuals diagnosed with psoriasis is projected to drive the expansion of the stelara (ustekinumab) market moving forward. Psoriasis is a persistent autoimmune condition where skin cell regeneration is accelerated, leading to characteristic red, flaky skin patches. This rise in prevalence can be attributed to various factors, including advancements in diagnosis, environmental triggers, genetic susceptibility, and an aging demographic. Stelara (ustekinumab) works by targeting and blocking interleukin-12 and interleukin-23, thereby assisting psoriasis sufferers through effective reduction of inflammation and plaque development, which results in clearer skin and sustained symptom control, ultimately improving their overall quality of life. For instance, according to an August 2024 report by the National Psoriasis Foundation (NPF), a US-based non-profit organization, psoriasis impacts approximately 3% of U.S. adults aged 20 and over, totaling more than 7. million individuals. Additionally, an estimated 600,000 adults in the country are believed to have psoriasis but remain undiagnosed. Consequently, the growing prevalence of psoriasis patients is anticipated to fuel the expansion of the stelara (ustekinumab) market.

What Segment Categories Are Evaluated In The Stelara (Ustekinumab) Market Study?

The stelara (ustekinumab) market covered in this report is segmented –

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications

2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Pediatric, Adult, Geriatric

What Trends Are Affecting The Growth Of The Stelara (Ustekinumab) Market?

Leading companies in the stelara (ustekinumab) market are actively developing innovative products, such as biosimilars to stelara, aiming to deliver a cost-effective treatment alternative for individuals with chronic inflammatory conditions. Stelara biosimilars are biologically similar medicines crafted to replicate the therapeutic effects of Stelara (Ustekinumab), by targeting IL-12 and IL-23, for treating autoimmune conditions like psoriasis and psoriatic arthritis. For instance, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is distinguished by its extensive indications, providing treatment for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. Notably, it is also indicated for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, demonstrating its adaptability across various age groups. This broad scope positions IMULDOSA as a significant choice for managing a range of immune-mediated inflammatory diseases.

Who Are The Key Market Participants In The Stelara (Ustekinumab) Market?

Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson

Access The Complete Stelara (Ustekinumab) Market Report:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

Which Geographic Region Represents The Largest Stelara (Ustekinumab) Market Share?

North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Stelara (Ustekinumab) Market During 2026–2030?

The stelara (ustekinumab) market size has demonstrated robust growth in recent years. It is projected to increase from $11.85 million in 2025 to $12.54 million in 2026, at a compound annual growth rate (CAGR) of 5.9%. The expansion observed historically stems from several factors, including the limitations of conventional immunosuppressants, the rising prevalence of autoimmune diseases, compelling clinical efficacy data, the practice of hospital-based biologic administration, and the ongoing demand for durable remission.

The market for stelara (ustekinumab) is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $15.57 million, demonstrating a compound annual growth rate (CAGR) of 5.5%. This projected growth during the forecast period is driven by several factors, including an increase in inflammatory bowel disease incidents, broader biologic reimbursement access, patient demand for less frequent administration, the influence of biosimilar competition, and advancements in biologic delivery systems. Key trends foreseen over this period encompass a heightened utilization of targeted biologic treatments, an broadening of indications for autoimmune diseases, a move towards sustained maintenance therapies, increasing acceptance of subcutaneous biologics, and a rise in self-administered treatments at home.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

Which Strong Drivers Are Impacting The Stelara (Ustekinumab) Market Growth?

An increasing number of individuals diagnosed with psoriasis is projected to drive the expansion of the stelara (ustekinumab) market moving forward. Psoriasis is a persistent autoimmune condition where skin cell regeneration is accelerated, leading to characteristic red, flaky skin patches. This rise in prevalence can be attributed to various factors, including advancements in diagnosis, environmental triggers, genetic susceptibility, and an aging demographic. Stelara (ustekinumab) works by targeting and blocking interleukin-12 and interleukin-23, thereby assisting psoriasis sufferers through effective reduction of inflammation and plaque development, which results in clearer skin and sustained symptom control, ultimately improving their overall quality of life. For instance, according to an August 2024 report by the National Psoriasis Foundation (NPF), a US-based non-profit organization, psoriasis impacts approximately 3% of U.S. adults aged 20 and over, totaling more than 7. million individuals. Additionally, an estimated 600,000 adults in the country are believed to have psoriasis but remain undiagnosed. Consequently, the growing prevalence of psoriasis patients is anticipated to fuel the expansion of the stelara (ustekinumab) market.

Which Segment Categories Are Included In The Stelara (Ustekinumab) Market Segment Analysis?

The stelara (ustekinumab) market covered in this report is segmented –

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications

2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Pediatric, Adult, Geriatric

Which Trends Are Contributing To Changes In The Stelara (Ustekinumab) Market?

Leading companies within the stelara (ustekinumab) market are developing innovative products, including biosimilars to stelara, to offer a cost-effective treatment alternative for patients with chronic inflammatory conditions. Stelara biosimilars are biologically analogous medications created to replicate the therapeutic effects of Stelara (Ustekinumab), by targeting IL-12 and IL-23 to manage autoimmune diseases like psoriasis and psoriatic arthritis. For instance, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical company, reported the U.S. Food and Drug Administration (FDA) approval of IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is distinguished by its wide range of indications, providing treatment for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. It also possesses a unique indication for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it adaptable across different age groups. This extensive coverage establishes IMULDOSA as a valuable option for managing various immune-mediated inflammatory diseases.

Who Are The Active Companies Shaping The Stelara (Ustekinumab) Market?

Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson

Get The Full Stelara (Ustekinumab) Market Report:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

Which Region Represents The Largest Share Of The Stelara (Ustekinumab) Market?

North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Stelara (Ustekinumab) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

Browse Through More Reports Similar to the Global Stelara (Ustekinumab) Market 2026, By The Business Research Company

Stevia Market Report 2026

https://www.thebusinessresearchcompany.com/report/stevia-global-market-report

Stearic Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/stearic-acid-global-market-report

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Stelara (Ustekinumab) Market During 2026–2030?

The market size for stelara (ustekinumab) has shown robust expansion over the past few years. This market is projected to expand from $11.85 million in 2025 to reach $12.54 million by 2026, exhibiting a compound annual growth rate (CAGR) of 5.9%. Factors contributing to this historical growth include the shortcomings of traditional immunosuppressants, an increasing incidence of autoimmune diseases, compelling clinical efficacy data, the practice of hospital-based biologic administration, and a persistent need for lasting remission.

The market size for stelara (ustekinumab) is projected to exhibit robust growth over the coming years. Its value is expected to reach $15.57 million by 2030, progressing at a compound annual growth rate (CAGR) of 5.5%. This anticipated expansion during the forecast period is attributable to an increase in inflammatory bowel disease cases, the broadening of biologic reimbursement coverage, patients’ preference for less frequent dosing, the influence of biosimilar competition, and advancements in biologic delivery devices. Significant trends identified for the forecast horizon include the rising utilization of targeted biologic therapies, an expansion of autoimmune disease indications, a transition toward long-term maintenance treatment, the increasing adoption of subcutaneous biologics, and a rise in home-based administration.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

Which Economic Or Industry Drivers Are Impacting The Stelara (Ustekinumab) Market?

The stelara (ustekinumab) market is projected to expand due to the increasing prevalence of psoriasis patients. Psoriasis is an autoimmune disorder that chronically accelerates skin cell turnover, resulting in red, scaly patches on individuals. Several factors contribute to this rise in prevalence, including better diagnosis methods, environmental triggers, genetic predispositions, and an aging demographic. Stelara (ustekinumab) works by targeting and inhibiting interleukin-12 and interleukin-23, which assists psoriasis patients by effectively reducing inflammation and plaque formation, leading to improved skin clearance and sustained symptom management, thereby enhancing their quality of life. For instance, in August 2024, a report by the National Psoriasis Foundation (NPF) revealed that psoriasis affects approximately 3% of U.S. adults aged 20 and above, which translates to over 7 million individuals. Additionally, it is estimated that around 600,000 adults in the country have psoriasis but have not yet been diagnosed. Therefore, the growing number of psoriasis patients is expected to drive the growth of the stelara (ustekinumab) market.

How Are The Various Segments Of The Stelara (Ustekinumab) Market Categorized?

The stelara (ustekinumab) market covered in this report is segmented –

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications

2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Pediatric, Adult, Geriatric

What Trends Are Affecting The Expansion Of The Stelara (Ustekinumab) Market?

Leading companies operating within the stelara (ustekinumab) market are actively developing innovative products, including biosimilars to stelara, to offer a more cost-effective treatment option for patients experiencing chronic inflammatory conditions. Stelara biosimilars are biologically analogous medications created to mimic the therapeutic effects of Stelara (Ustekinumab) by targeting IL-12 and IL-23, specifically for treating autoimmune conditions such as psoriasis and psoriatic arthritis. For example, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval of IMULDOSA (ustekinumab-srlf), which is a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is distinguished by its broad range of indications, providing treatment for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. It also carries a distinct indication for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, demonstrating its versatility across different age groups. This extensive coverage positions IMULDOSA as a valuable alternative for managing various immune-mediated inflammatory diseases.

Which Major Firms Influence Developments In The Stelara (Ustekinumab) Market?

Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson

Read the full stelara (ustekinumab) market report here:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

What Are The Top-Performing Regions Within The Stelara (Ustekinumab) Market?

North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Stelara (Ustekinumab) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19935&type=smp

Browse Through More Reports Similar to the Global Stelara (Ustekinumab) Market 2026, By The Business Research Company

Stevia Market Report 2026

https://www.thebusinessresearchcompany.com/report/stevia-global-market-report

Stearic Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/stearic-acid-global-market-report

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the stelara (ustekinumab) market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Stelara (Ustekinumab) Market expected to grow between 2026 and 2030?

The market size for stelara (ustekinumab) has experienced substantial growth in recent years. This market is expected to expand from $11.85 million in 2025 to $12.54 million in 2026, at a compound annual growth rate (CAGR) of 5.9%. Historically, this growth can be attributed to factors such as the limitations of conventional immunosuppressants, the increasing prevalence of autoimmune diseases, robust clinical efficacy data, hospital-based biologic administration, and the demand for durable remission.

The market for stelara (ustekinumab) is projected to experience robust expansion over the coming years, with its valuation anticipated to reach $15.57 million by 2030, driven by a compound annual growth rate (CAGR) of 5.5%. This projected growth during the forecast period can be primarily attributed to several factors, including an increase in inflammatory bowel disease cases, broader biologic reimbursement coverage, patients’ preference for less frequent dosing, the impact of biosimilar competition, and advancements in biologic delivery devices. Key trends for the upcoming period encompass the increasing application of targeted biologic therapies, the broadening of autoimmune disease indications, a transition towards long-term maintenance treatments, the rising uptake of subcutaneous biologics, and an increase in administration at home.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

Which Drivers Are Influencing Market Acceleration In The Stelara (Ustekinumab) Market?

An increasing number of individuals affected by psoriasis is anticipated to drive the expansion of the stelara (ustekinumab) market moving forward. Psoriasis patients are defined as those experiencing a chronic autoimmune condition characterized by accelerated skin cell regeneration, leading to the development of red, scaly patches. This growing prevalence of psoriasis sufferers can be attributed to multiple factors, including enhanced diagnostic methods, environmental triggers, inherited genetic factors, and an increasingly older demographic. stelara (ustekinumab) functions by targeting and inhibiting interleukin-12 and interleukin-23, thereby assisting psoriasis patients through effective reduction of inflammation and plaque development, which contributes to clearer skin and sustained symptom control, ultimately boosting their quality of life. For example, a report released by the National Psoriasis Foundation (NPF), a U.S.-based non-profit organization, indicated that in August 2024, psoriasis impacts approximately 3% of U.S. adults aged 20 and above, amounting to over 7 million individuals. Furthermore, it is estimated that about 600,000 adults within the nation suffer from psoriasis yet have not received a diagnosis. Consequently, the escalating prevalence of psoriasis patients is expected to stimulate the growth of the stelara (ustekinumab) market.

What Leading Segments Are Studied In The Stelara (Ustekinumab) Market?

The stelara (ustekinumab) market covered in this report is segmented –

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications

2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Pediatric, Adult, Geriatric

Which Trends Are Expected To Influence The Stelara (Ustekinumab) Market In The Upcoming Years?

Major companies engaged in the stelara (ustekinumab) market are developing innovative offerings, including biosimilars to stelara, to provide a cost-effective therapeutic choice for patients with chronic inflammatory ailments. Stelara biosimilars are biologically analogous drugs created to replicate the therapeutic benefits of Stelara (Ustekinumab), designed to target IL-12 and IL-23 for treating autoimmune conditions such as psoriasis and psoriatic arthritis. For instance, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical organization, announced the U.S. Food and Drug Administration (FDA) approval for IMULDOSA (ustekinumab-srlf), which is a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is distinguished by its wide-ranging indications, offering treatment for adult patients suffering from moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. It also has a unique indication for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it highly adaptable across different age demographics. This extensive applicability establishes IMULDOSA as a valuable alternative for addressing various immune-mediated inflammatory diseases.

Which Key Players Are Driving Competition In The Stelara (Ustekinumab) Market?

Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

Which Region Is Projected To Lead The Stelara (Ustekinumab) Market During The Forecast Period?

North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Stelara (Ustekinumab) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19935&type=smp

Browse Through More Reports Similar to the Global Stelara (Ustekinumab) Market 2026, By The Business Research Company

Stevia Market Report 2026

https://www.thebusinessresearchcompany.com/report/stevia-global-market-report

Stearic Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/stearic-acid-global-market-report

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Stelara (Ustekinumab) Market Growth Performance Trended Historically, And What Lies Ahead?

The market size of stelara (ustekinumab) has seen significant growth in the recent past. The projected growth will take the market from a worth of $11,177.34 million in 2024 to being valued at $11,850.79 million in 2025, with a compound annual growth rate (CAGR) of 6.0%. The expansion during the historical period is credited to factors such as the increase in healthcare expenditure, development of specialty drug delivery methods, widening of clinical trial initiatives, investments in research and development, and the rising employment of telemedicine for easier treatment access.

What Is the Forecast for the Stelara (Ustekinumab) Market Size Through 2029?

Anticipations for the stelara (ustekinumab) market forecast suggest robust expansion in the coming years, leading to a size of $14,768.48 million by 2029, with a compound annual growth rate (CAGR) of 5.7%. This projected growth throughout the forecast period is credited to the broadening applications for stelara, the escalating occurrence of autoimmune diseases, the drug’s superior effectiveness in refractory instances compared to other options, increasing consciousness among both patients and medical practitioners, and an expanding emphasis on bespoke medicine. The period is expected to witness significant shifts such as the embracement of biologic treatments, the advent of state-of-the-art drug delivery systems, data-centric healthcare systems, collaborations, and licensure contracts among pharmaceutical firms, and progress in biologics production techniques.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

What are the Key Market Players in Stelara (Ustekinumab) Market and How They’re Evolving?

Major companies operating in the stelara (ustekinumab) market include Johnson & Johnson

What Are the Primary Growth Drivers in the Stelara (Ustekinumab) Market?

An increase in the number of individuals suffering from psoriasis, a chronic autoimmune disorder that fastens the turnover of skin cells, is anticipated to fuel the growth of the Stelara (ustekinumab) market. Several factors account for this increase in psoriasis cases, such as enhanced diagnostic methods, environmental causes, genetic susceptibility, and an elderly population. Stelara (ustekinumab) works by targeting and hindering interleukin-12 and interleukin-23, which assists psoriasis patients by effectively diminishing inflammation and plaque development. This results in better skin clearance and long-term symptom management, thus, enriching their overall lifestyle quality. For example, a report by the US-based National Library of Medicine, released in May 2024, showed that the prevalence of psoriasis grew to 0.221% in 2022, with 6,930 PsA instances recorded in a 3,133,500 strong population. Hence, the surge in the number of psoriasis patients is foreseen to further boost the expansion of the Stelara (ustekinumab) market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=19935&type=smp

What Are the Leading Segments in the Global Stelara (Ustekinumab) Industry?

The stelara (ustekinumab)market covered in this report is segmented –

1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn’s Disease; Ulcerative Colitis; Other Indications

2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

4) By End User: Pediatric; Adult; Geriatric

What Are the Key Market Trends in the Stelara (Ustekinumab) Industry?

The primary development in the Stelara (ustekinumab) market pertains to the creation of novel products, such as Stelara biosimilars, to supply affordable treatment solutions for patients suffering from chronic inflammatory diseases. Biosimilars of Stelara are essentially similar biomedicines formulated to mimic the curative impact of Stelara (Ustekinumab), specifically targeting IL-12 and IL-23 to handle autoimmune diseases like psoriasis and psoriatic arthritis. For example, Accord BioPharma Inc., an American biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) in October 2024 for IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is noted for its wide range of indications— it can treat adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, seriously active Crohn’s disease, and ulcerative colitis. Uniquely, it is also suitable for pediatric patients aged 6 years and above suffering from moderate to severe plaque psoriasis and active psoriatic arthritis, thus proving its utility across various age groups. This extensive scope makes IMULDOSA a very viable prospect for managing a diverse array of immune-mediated inflammatory conditions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

What Is the Regional Outlook for the Stelara (Ustekinumab) Market?

North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19935

This Report Delivers Insight On:

1. How big is the stelara (ustekinumab) market, and how is it changing globally?

2. Who are the major companies in the stelara (ustekinumab) market, and how are they performing?

3. What are the key opportunities and risks in the stelara (ustekinumab) market right now?

4. Which products or customer segments are growing the most in the stelara (ustekinumab) market?

5. What factors are helping or slowing down the growth of the stelara (ustekinumab) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the stelara (ustekinumab) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Fast Is The Stelara (Ustekinumab) Market Expected to Grow Between 2025 And 2029?

In recent times, the market for Stelara (ustekinumab) has seen robust growth. It is projected to escalate from $11,177.34 million in 2024 to $11,850.79 million in 2025, marking a compound annual growth rate (CAGR) of 6.0%. The notable growth during the historical period can be credited to increased healthcare expenditure, the expansion of specialty pharmaceutical distribution channels, broadening clinical trial initiatives, investment in research and innovation, and the rising use of telemedicine for easier treatment access.

In the coming years, the market size of Stelara (ustekinumab) is projected to undergo significant expansion, growing to $14,768.48 million in 2029 with a compound annual growth rate (CAGR) of 5.7%. The escalation during the forecast period can be credited to a broader range of indications for Stelara, the growing prevalence of autoimmune diseases, superior efficacy in resistant cases in comparison to other options, enhanced patient and healthcare provider awareness, and increased emphasis on tailored medicine. Foreseeable trends for this period encompass the adoption of biologic therapies, the evolution of enhanced drug delivery systems, data-guided healthcare structures, collaborative and licensing alliances amongst pharmaceutical corporations, and breakthroughs in biologic manufacturing technologies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Stelara (Ustekinumab) Market?

The increase in the incidence of psoriasis patients is anticipated to boost the stelara (ustekinumab) market’s expansion in the future. These patients have an autoimmune disorder that speeds up skin cell regeneration, causing red, flaky patches. The escalated prevalence of this condition can be linked to factors such as more accurate diagnosis, environmental causative agents, genetic tendencies, and a growing elderly population. Stelara (ustekinumab) works by thwarting interleukin-12 and interleukin-23, thereby assisting psoriasis patients by effectively mitigating inflammation and plaque accumulation. This leads to better skin clearance and lasting symptom control, ultimately improving their life quality. For example, a publication by the National Library of Medicine, a medical library based in the US, revealed that the incidence of psoriasis escalated to 0.221% in 2022, with a report of 6,930 PsA cases among a population of 3,133,500 in May 2024. Hence, the increased incidence of psoriasis patients is projected to drive the expansion of the stelara (ustekinumab) market.

Which Segments in the Stelara (Ustekinumab) Offer the Most Growth?

The stelara (ustekinumab)market covered in this report is segmented –

1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn’s Disease; Ulcerative Colitis; Other Indications

2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

4) By End User: Pediatric; Adult; Geriatric

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19935&type=smp

What Are the Fastest-Growing Geographies in the Stelara (Ustekinumab) Market?

North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Stelara (Ustekinumab) Industry?

One prominent trend in the Stelara (Ustekinumab) market is the introduction of unique products, such as biosimilars to Stelara, designed to offer affordable treatment solutions for individuals with chronic inflammatory diseases. These Stelara biosimilars are biologically comparable medicines designed to mimic the healing impacts of Stelara (Ustekinumab) by targeting IL-12 and IL-23 to combat autoimmune disorders like psoriasis and psoriatic arthritis. To illustrate, in October 2024, Accord BioPharma Inc., an American biopharmaceutical firm, garnered approval from the U.S. Food and Drug Administration (FDA) for IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is noteworthy for its extensive indications, providing therapies for mature patients dealing with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to enormously active Crohn’s disease, and ulcerative colitis. Remarkably, it is also certified for use in pediatric patients over 6 years old with moderate to severe plaque psoriasis and active psoriatic arthritis, showcasing its flexibility across different ages. This comprehensive applicability situates IMULDOSA as a useful alternative for managing a myriad of immune-driven inflammatory diseases.

View the full report here:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

What Are the Key Elements That Define the Stelara (Ustekinumab) Market?

Stelara (Ustekinumab) is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), key proteins involved in inflammatory and autoimmune responses. It is widely used to treat conditions such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19935

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theStelara (Ustekinumab) Market?

An increase in the number of individuals suffering from psoriasis is anticipated to propel the stelara (ustekinumab) market’s growth. Patients with psoriasis endure a persistent autoimmune disorder that accelerates the turnover of skin cells, leading to red, scaly skin patches. The increased incidence of psoriasis can be associated with multiple factors like improved diagnostic procedures, environmental triggers, genetic factors, and an older population demographic. Interleukin-12 and interleukin-23, targeted and inhibited by stelara (ustekinumab), help these patients by efficaciously reducing inflammation, restricting plaque formation, and promoting enhanced skin clarity and long-term symptom management, ultimately improving their life quality. For instance, a report released by the National Library of Medicine, a medical library based in the US, revealed in May 2024 that psoriasis prevalence had grown to 0.221% in 2022, with a documented 6,930 PsA instances in a populace of 3,133,500. Thus, escalating psoriasis prevalence is forecasted to significantly drive the stelara (ustekinumab) market’s growth.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

How Has the Stelara (Ustekinumab) Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

The stelara (ustekinumab) market has expanded significantly, moving from $11,177.34 million in 2024 to $11,850.79 million in 2025 at a CAGR of 6.0%. Growth was driven by increased healthcare budgets, the rise of specialty drug channels, broader clinical research efforts, higher R&D investments, and telemedicine-based treatment access.

The stelara (ustekinumab) market will reach $14,768.48 million by 2029 with a 5.7% CAGR, fueled by wider usage in autoimmune disorders and its effectiveness in refractory cases. Trends include biologics innovation, new delivery methods, and pharma collaborations.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19935

What Are the Current Market Growth and Trends in theStelara (Ustekinumab) Market That Industry Players Should Watch?

One significant trend within the Stelara (Ustekinumab) market is the development of innovative substitutes like biosimilars to Stelara, offering more affordable cure alternatives for patients with chronic inflammatory illnesses. Biosimilars of Stelara are bio-equivalent drugs crafted to copy the therapeutic properties of Stelara (Ustekinumab), influencing IL-12 and IL-23 to combat autoimmune diseases like psoriasis and psoriatic arthritis. For example, Accord BioPharma Inc., a biopharmaceutical firm based in the United States, unveiled in October 2024 the U.S. Food and Drug Administration’s (FDA) approval for IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is recognized for its extensive indications, catering to adult patients suffering from moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. Moreover, it’s distinctly prescribed for pediatric patients at least six years old suffering from moderate to severe plaque psoriasis and active psoriatic arthritis, making it adaptable for various age groups. Such extensive adaptability places IMULDOSA as an invaluable solution for controlling different immune-mediated inflammatory disorders.

What Are the Major Market Players Making an Impact on theStelara (Ustekinumab) Market Growth?

Major companies operating in the stelara (ustekinumab) market include Johnson & Johnson

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

How Are the Key Segments of the Stelara (Ustekinumab) Market Driving Opportunities and Innovations?

The stelara (ustekinumab)market covered in this report is segmented –

1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn’s Disease; Ulcerative Colitis; Other Indications

2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

4) By End User: Pediatric; Adult; Geriatric

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=19935&type=smp

What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theStelara (Ustekinumab) Market?# Market Expansion?

North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Stelara (Ustekinumab) Market 2025, By The Business Research Company:

Psoriasis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Radiosurgery And Radiotherapy Robotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/radiosurgery-and-radiotherapy-robotics-global-market-report

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Enjoy a flat 15% OFF on all 2025 Global Market Reports until March 31st! Use code FY25SAVE to save big—don’t miss out!

How has the stelara (ustekinumab) market size evolved in recent years?

In recent times, the market size for stelara (ustekinumab) has experienced significant growth. Its projected growth will see an escalation from a monetary value of $11,177.34 million in 2024 to $11,850.79 million in 2025, representing a compound annual growth rate (CAGR) of 6.0%. Factors such as an increase in healthcare expenditure, the development of special medicine distribution channels, expansion of clinical trial programs, investment in R&D, and broader access to treatment through telemedicine have contributed to the historic growth.

What are the predictions for the stelara (ustekinumab) market size in the coming years?

The market size for stelara (ustekinumab) is anticipated to experience significant growth in the coming years, reaching a value of $14,768.48 million in 2029 with a compound annual growth rate (CAGR) of 5.7%. This predicted growth during the forecast period is due to several factors including the increasing use of stelara for various indications, a rise in cases of autoimmune diseases, its superior efficacy in refractory situations compared to other options, increased awareness among patients and medical professionals, and an amplified focus on personalized medicine. Main trends throughout the forecast period involve the incorporation of biologic therapies, the progression of advanced drug delivery systems, data-centric healthcare systems, collaborations and licenses among pharma firms, and improvements in biologics production technologies.

Get your stelara (ustekinumab) market report here!

https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

What key factors are fueling the growth of the stelara (ustekinumab) market?

The increase in the number of individuals battling psoriasis, a chronic autoimmune condition that causes rapid skin cell turnover and results in red, flaky skin patches, is likely to drive the expansion of the stelara (ustekinumab) market. Several factors, including enhanced diagnostic techniques, environmental factors, genetic susceptibility, and an aging demographic, contribute to this growth of psoriasis cases. By effectively inhibiting interleukin-12 and interleukin-23, stelara (ustekinumab) helps psoriasis patients minimize inflammation and plaque formation, leading to better skin health, longer relief from symptoms, and ultimately an improved quality of life. For example, a report by the National Library of Medicine, a U.S.-based medical library, highlighted that in 2024 the incidence of psoriasis elevated to 0.221%, with a total of 6,930 PsA incidents reported out of a population of 3,133,500 in 2022. Consequently, the growing number of psoriasis patients is anticipated to steer the growth of the stelara (ustekinumab) market.

How is the global stelara (ustekinumab) market divided into key segments?

The stelara (ustekinumab)market covered in this report is segmented –

1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn’s Disease; Ulcerative Colitis; Other Indications

2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

4) By End User: Pediatric; Adult; Geriatric

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

Who are the key firms paving the way for growth in the stelara (ustekinumab) market?

Major companies operating in the stelara (ustekinumab) market include Johnson & Johnson

Which trends are expected to transform the stelara (ustekinumab) market?

The significant trend in the Stelara (Ustekinumab) market involves the creation of innovative products like Stelara biosimilars to provide affordable therapeutic options to patients with chronic inflammatory conditions. Stelara biosimilars, which are biologically similar drugs designed to mimic the therapeutic effects of Stelara, target IL-12 and IL-23 to treat autoimmune diseases like psoriasis and psoriatic arthritis. As an example, Accord BioPharma Inc., an American biopharmaceutical firm, announced in October 2024 that the U.S Food and Drug Administration (FDA) had granted approval for IMULDOSA (ustekinumab-srlf), a Stelara biosimilar. Notably, IMULDOSA’s broad therapeutic indications include treatment for adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. Uniquely, it also extends to pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis. This wide-ranging applicability situates IMULDOSA as a useful resource for handling multiple immune-mediated inflammatory diseases.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19935

What regions are contributing significantly to the growth of the stelara (ustekinumab) market?

North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Psoriasis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Radiosurgery And Radiotherapy Robotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/radiosurgery-and-radiotherapy-robotics-global-market-report

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: